)
Tonix Pharmaceuticals (TNXP) investor relations material
Tonix Pharmaceuticals TD Cowen 46th Annual Health Care Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Key product and market updates
Focused on the launch of Tonmya, a first-in-class, sublingual treatment for fibromyalgia, approved in August and launched in November, with $1.4 million in net sales reported for the initial period.
Tonmya targets disturbed sleep in fibromyalgia, addressing a high unmet need among an estimated 10 million U.S. adults, with potential expansion to long COVID patients.
Commercial strategy includes 90 field reps targeting the top 5% of prescribers, robust patient access programs, and a WAC of $1,860/month.
Existing migraine products Tosymra and Zembrace are being deprioritized in promotion.
Company maintains $208 million in cash, no debt, and a simple capital structure.
Clinical and scientific insights
Tonmya’s unique sublingual, transmucosal formulation enables durable pain relief, with clinical trials showing significant and clinically meaningful reductions in pain.
Most common side effects are mild oral symptoms; no weight, blood pressure, cognitive, or sexual dysfunction changes observed.
Tonmya is a non-opioid analgesic, aligning with healthcare priorities to reduce opioid use in chronic pain.
Fibromyalgia is underdiagnosed and undertreated, with many patients receiving inappropriate opioid prescriptions.
Educational efforts aim to improve prescriber knowledge and promote holistic treatment approaches.
Pipeline and future plans
Advancing a Lyme disease prophylactic (licensed from UMass) with a planned human challenge study in 2027; aims for annual dosing.
TNX-102 SL being developed for major depressive disorder (study starting mid-year) and acute stress disorder (in partnership with UNC, DoD-funded).
Additional programs include a monoclonal antibody for kidney transplant (phase II starting mid-year) and an intranasal oxytocin for Prader-Willi syndrome (study planned for Q1 2027).
Multiple partnerships with leading institutions support pipeline development.
Company expects significant milestones in 2026 and 2027, including key clinical trial initiations.
Next Tonix Pharmaceuticals earnings date
Next Tonix Pharmaceuticals earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)